# Microbiotica

> Clinical-stage developer of oral precision microbiome medicines.

## Why it is interesting

Its £36 million Series C first close funds a larger clinical test of MB310 after company-reported Phase 1b signals. The investment thesis depends on reproducible patient benefit, consistent bacterial manufacturing and a clinically differentiated product—not merely platform breadth.

## Profile

- **Latest funding:** Series C — first close — £36M / $48M (October 16, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $48M
- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-10-16T23:10:55.984Z
- **Latest funding investors:** British Business Bank, Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, Seventure Partners

## Key facts

- Oct 16, 2026: £36M/$48M Series C first close led by British Business Bank
- All existing Series B investors participated; valuation and final target undisclosed
- Proceeds support MB310's planned Phase 2 study in ulcerative colitis
- MB097 is also being evaluated in an early-stage melanoma study; neither program is an approved treatment

## Funding history

- Series C — first close · £36M / $48M · October 16, 2026
  Source: https://www.globenewswire.com/news-release/2026/10/16/3382257/0/en/microbiotica-raises-36-million-48-million-in-series-c-financing-to-advance-pipeline-into-phase-2-clinical-development.html

## Investors in our directory

- https://venturecapitaltracker.com/fund/british-business-bank
- https://venturecapitaltracker.com/fund/tencent-investment
- https://venturecapitaltracker.com/fund/ip-group
- https://venturecapitaltracker.com/fund/cambridge-innovation-capital
- https://venturecapitaltracker.com/fund/flerie
- https://venturecapitaltracker.com/fund/seventure-partners

## Related articles

- https://venturecapitaltracker.com/microbiotica-36m-series-c-first-close-mb310

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 16, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/microbiotica